- Details
- Description
-
Packaging Size56c/bottle
-
Strength150mg
-
CompositonAlectinib
-
TreatmentAnaplastic lymphoma kinase (ALK)-positive metastasis non-small cell lung cancer (NSCLC)
-
FormCapsule
-
BrandAlynni
-
Quantity Unit150mg*56C/Bottle
-
ManufacturerTongmeng (Lao) Pharmaceutical & Food Co., Ltd.(TLPH)
Alectinib is a type of cancer growth blocker called a tyrosine kinase inhibitor. It works by blocking certain chemical messengers that tell cells to grow. This stops or slows down the cancer.
Non-small Cell Lung Cancer
Indicated for anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test
600 mg PO BID until disease progression or unacceptable toxicity
See Administration
Dosage Modifications
Dose reduction schedule
- Starting dose: 600 mg PO BID
- First dose reduction: 450 mg PO BID
- Second dose reduction: 300 mg PO BID
- Discontinue if patients are unable to tolerate 300 mg PO BID